October 13, 2021

Health Care and Life Science IPOs are Soaring. Should Your Company Climb Aboard?

The recent proliferation of initial public offerings (IPOs) by health care and biotechnology companies is sparking interest among leadership in similar organisations and causing them to wonder whether offering stock to the public to fuel future growth.

This path to expansion and business opportunities has been quite popular lately.

According to data compiled by S&P Global Market Intelligence, 112 global health care and life science (HLS) companies went public globally in the second quarter, more than doubling the number of IPOs in the same quarter in the previous year. The total valuation of these offerings was $28.8 billion — more than half of the combined offering sizes of IPOs in the entirety of 2020 — with the lion’s share of the group consisting of IPOs of health care services and biotechnology companies. Furthermore, the average offering value per IPO increased significantly over the past six years, from $1.44 billion in the second quarter of 2016 to $15.64 billion in the second quarter of 2021.

Click here to read the full insight

Thought Leadership

Social Care M&A Market

April 25, 2025

The social care sector is a cornerstone of society, contributing £50 billion annually to the UK economy. It plays a vital role in supporting the well-being and diverse needs of our population. However, it now stands at a critical juncture.

Thought Leadership

GLOBAL CONSUMER HEALTH M&A MARKET

February 27, 2025

The Consumer Health market, currently valued at over $357 billion globally, is projected to almost double by 2034. Through 2025 and onwards, the Consumer Health market is poised for steady growth. The currently fragmented sector offers potential for roll-up opportunities, driven by widespread demand for an integrated offering.

Thought Leadership

CONTRACT DEVELOPMENT AND MANUFACTURING ORGANISATIONS M&A MARKET

December 2, 2024

The global Contract Development and Manufacturing Organisations (CDMOs) market, which helps Pharmaceutical and MedTech companies in efficiently developing, manufacturing, and bringing products to market, is valued at $230 billion in 2024, and is anticipated to grow at a CAGR of 8.5% to reach $358 billion by 2029.

Thought Leadership

THE OCCUPATIONAL HEALTH M&A MARKET

November 18, 2024

According to the Institute of Public Policy Research, presenteeism, or working whilst sick, cost the UK economy £25bn in 2023, whilst absenteeism cost an additional £5bn. To address these challenges, many workplaces now emphasise proactive, value-added services for employee wellbeing and performance, delivered both on-site and online. This shift has spurred growth in the Occupational Health market, attracting significant interest from financial investors and strategic acquirers.

Featured Experts